Human biospecimens: consent scope is the deliverable, and it is not on the invoice

Buyers of human tissue routinely acquire material they are not permitted to use the way they planned. Not because anyone misled them, because consent scope is invisible until deep into a procurement conversation, and by then the specimen has been selected on the basis of tissue type, donor demographics and price.

The three things a purchaser asks about first are tissue type, quantity and cost. The thing that determines whether the project is publishable, or commercialisable, or neither, is what the donor agreed to. That document exists, it is specific, and it does not appear on the invoice.

In this category the ethics and consent documentation is the deliverable as much as the tissue is. A supplier who cannot produce it quickly is a different kind of supplier rather than a cheaper one.

What is publicly priced: almost nothing

That one distributor-visible figure deserves the caution attached to it. It is an assay kit, not a specimen. It moved twice within a single day of observation. It tells you roughly what a packaged adipose explant product costs through a distribution channel, which is a useful order-of-magnitude anchor and nothing more. Do not build a budget on it, and re-check it at quote time.

Everything else in this category is quoted, and it is quoted because a biospecimen price is a function of cohort definition rather than of catalogue. A liver sample from a 45-year-old with a specific comorbidity, collected within a defined window, with matched serology and clinical annotation, is not a SKU. Asking a supplier to publish a price for it is asking them to publish a price for a thing that does not exist until you define it.

Banked inventory or prospective collection: the question that sets the price

This is the single decision that most affects cost and schedule, and it has a clean decision rule.

Buy from banked inventory when the pre-analytical variables are not part of your experiment. The material exists, it can be searched, it ships in around two weeks, and it costs what it costs.

Fund prospective collection when time to freeze, anticoagulant choice, processing method, collection window or clinical timepoint is a factor you are measuring or must control. Then you are not buying a specimen; you are buying a protocol executed on your behalf, and the recruitment is the expensive part.

The reason this matters is that pre-analytical handling genuinely changes what is measurable. Work on the effect of cold ischemia time on hypoxia, epithelial-mesenchymal transition and apoptosis pathways in normal colon mucosa (PMC13004397) demonstrates that the interval between removal and preservation alters the biology you subsequently measure. Work on pre-analytical factors affecting nucleic acid integrity in biobanked fresh frozen tissue (PMC12634257) makes the same point for molecular endpoints.

So the decision is not about quality, banked material is not lower quality. It is about whether the handling history is a variable you need to own. If it is, prospective collection is the only correct purchase and funding it is not optional. If it is not, prospective collection is money wasted, and a supplier who lets you fund it anyway has not asked you the right question.

The consent scope conversation, in the first email

Here is the question that should go out before the tissue type is even settled:

“What consent scope attaches to this material, does it cover commercial use, does it cover genomic analysis, and does it permit the specific downstream use I have described?”

Three scopes commonly appear and they are not interchangeable:

• Research use only. The narrowest. Publishable, generally, subject to any additional restriction. Nothing commercial.
• Genomic analysis permitted. A separate permission from research use generally. Some consents explicitly exclude sequencing, and a project that plans to sequence and discovers this at submission has a problem no amount of budget solves.
• Commercial use permitted. The scope required if the work supports a product, a service sold for consideration, or an application. Rarer, and it is what makes some material more expensive than otherwise identical material.

The academic literature on biobank consent explains why this varies so much: the design of an informed consent document is an active and contested area, addressed in work on informed consent in newly established biobanks (PMC6843661), in a participatory study improving consent document templates for biobank research (PMC5738718), and in the published account of building the Partners HealthCare Biobank including its informed consent and return-of-results framework (PMC4810381).

The operational implication is that there is no standard consent across suppliers or across collections within a supplier. Each collection has its own document. Ask for the applicable one, in writing, per lot, before you order.

The regulatory posture a serious supplier holds

Cook MyoSite publishes the compliance position that any serious human tissue supplier must be able to state, and it is worth using as the benchmark against which to assess others:

• Cadaveric material from UNOS-registered, AOPO-accredited organ procurement organisations, with documented next-of-kin authorisation.
• Living donor tissue under an IRB-approved, physician-led protocol with written informed consent.

Those are specific, checkable statements. A supplier who describes their sourcing as “ethically obtained” or “fully consented” without naming the accrediting bodies, the authorisation mechanism and the protocol governance is making a claim rather than a disclosure.

The checklist version, to send to any prospective supplier: name the procurement organisations and their accreditations; state the authorisation mechanism for cadaveric material; confirm IRB approval and provide the protocol number for living donor collection; confirm who holds the IRB and whether your institution needs its own.

That last point catches people. Your receiving institution may require its own ethics review or a determination of non-human-subjects research even for commercially obtained material. Find out early

• it is a longer pole than shipping.

Chain of custody and the collection-to-preservation record

The specification that separates a usable specimen from a disappointing one, and it is frequently omitted from the request.

Ask for the collection-to-preservation time, per specimen, as a recorded number rather than a policy statement. “Processed promptly” is not data. A recorded interval is, and it lets you exclude outliers or model the effect rather than discovering it as unexplained variance.

Ask for the chain-of-custody record. Who handled the specimen, when, at what temperature, through how many transfers. For any longitudinal or multi-site design this is the document that makes your specimens comparable to each other.

Ask for the preservation method precisely: fresh in what medium at what temperature, snap frozen in what, fixed in what for how long, embedded how. “Frozen” covers several processes with different consequences for different endpoints.

Ask whether viable cells are required, because that constrains everything upstream. A specimen adequate for histology may be useless for cell isolation, and the difference is decided at collection rather than at shipping.

Matched material and disease-state cohorts

Two specifications that are available and under-requested.

Matched samples from the same donor. Several sample types from one individual removes a confound that unmatched material introduces, and it is orderable rather than being a research collaboration. The routes are set out in the matched donor material datasheet.

Disease-state donors. ZenBio has supplied human dermal fibroblasts including Type 2 diabetic donors since 1995 and advertises custom procurement where a specific donor phenotype is the requirement. If the phenotype is the experiment, say so in the enquiry rather than filtering a standard inventory and hoping.

The general principle in this category: the suppliers can do considerably more than their websites advertise, because the website advertises inventory and the business is procurement. Custom collection to a written specification is normal commercial practice here, not a favour. The most common failure is a buyer who assumes it is not available, does not ask, and either over-engineers a cultured substitute or spends months sourcing informally.

Buy tissue, or buy cells isolated from it

Worth deciding explicitly rather than by default.

Buy the tissue when you need the tissue, histology, matrix, mechanical properties, explant culture, or an isolation protocol that is itself part of the science.

Buy cells isolated from tissue when you need cells. Isolation is a skill, it has a yield, and the yield is variable. Several suppliers, Cell Applications, ScienCell, iXCells, Cook MyoSite, run custom isolation lines and will isolate from customer-specified tissue and donor profiles, with expansion, freezing, documentation and testing included. That route is covered in custom cell isolation.

The arithmetic is usually favourable to buying cells if cells are what you want. An in-house isolation that fails consumes the specimen, and the specimen is the part that cannot be re-ordered.

QC checklist

• Donor consent documentation, in writing, per lot, with the scope stated explicitly against your intended use.
• IRB or ethics approval documentation, including the protocol identifier for prospectively collected material.
• Confirmation of whether your own institution requires an ethics determination for receipt.
• Serology and infectious disease screening results, with agents named per the supplier’s protocol.
• Chain-of-custody record from collection through to shipment.
• Collection-to-preservation time, recorded per specimen as a number.
• Preservation method stated precisely: medium, temperature, fixative, duration, embedding.
• Donor demographics, age, sex, ethnicity, BMI, and disease state, with the clinical annotation you contracted for.
• Quantity per specimen and the number of unique donors, confirmed rather than assumed.
• Whether viable cells are required, and the supplier’s evidence that the handling supports it.
• Cold chain documentation for the shipment, with temperature logging where the endpoint is sensitive to it.
• Import and export documentation where the shipment crosses a border.

Specification checklist for a biospecimen quote

• Tissue or fluid type and anatomical site, precisely.
• Donor demographics and disease state, with which fields are mandatory and which are preferred stated separately, because everything mandatory narrows the pool and raises the price.
• Fresh, frozen, fixed, or viable-cell requirement, stated with the preservation method.
• Quantity per specimen and number of unique donors. These are two separate numbers and buyers routinely give only one.
• Banked inventory or prospective collection, decided against whether pre-analytical handling is part of your experiment.
• Acceptable collection-to-preservation window, as a number, where handling matters.
• Consent scope required: research use, commercial use, genomic analysis, listed explicitly.
• IRB and ethics documentation required, including whether your institution needs its own determination.
• Matched clinical annotation or serology required, field by field.
• Whether matched material from the same donor across sample types is required.
• Delivery schedule and shelf life on arrival, particularly for fresh material.

Where to go next

The datasheet, unit, lead time and QC scope, is at human-biospecimens. The supplier landscape, including which vendors block verification, is in biospecimen suppliers. If cells rather than tissue are the actual requirement, custom cell isolation covers that route, and shipping live cells and tissue covers the cold chain. For blood-derived material specifically, see human blood, leukopaks and apheresis products.

How we can help

The work in this category is not price comparison, because there are no prices. It is writing a cohort specification precise enough that three suppliers answer the same question, and getting the consent scope in writing before anyone commits.

Tell us the tissue, the donor constraints, the preservation requirement and, most importantly, what you intend to do with the material including whether anything downstream will be sold or sequenced, and we will scope the enquiry, put it to suppliers in comparable form, obtain the consent and ethics documentation up front, and tell you honestly when prospective collection is being sold to you and banked inventory would do.